PL3179982T3 - Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku - Google Patents

Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku

Info

Publication number
PL3179982T3
PL3179982T3 PL15827671.7T PL15827671T PL3179982T3 PL 3179982 T3 PL3179982 T3 PL 3179982T3 PL 15827671 T PL15827671 T PL 15827671T PL 3179982 T3 PL3179982 T3 PL 3179982T3
Authority
PL
Poland
Prior art keywords
drug
increasing bioavailability
prolonging
ophthalmic action
action
Prior art date
Application number
PL15827671.7T
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
Arindam Halder
Original Assignee
Sun Pharma Advanced Research Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Ltd filed Critical Sun Pharma Advanced Research Company Ltd
Publication of PL3179982T3 publication Critical patent/PL3179982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15827671.7T 2014-07-28 2015-07-24 Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku PL3179982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2437MU2014 2014-07-28
IN2206MU2015 2015-06-09
PCT/IN2015/050076 WO2016016908A1 (en) 2014-07-28 2015-07-24 Method of increasing bioavailability and/or prolonging ophthalmic action of a drug

Publications (1)

Publication Number Publication Date
PL3179982T3 true PL3179982T3 (pl) 2023-09-25

Family

ID=55216857

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15827671.7T PL3179982T3 (pl) 2014-07-28 2015-07-24 Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku

Country Status (6)

Country Link
US (4) US10172852B2 (pl)
EP (2) EP3179982B1 (pl)
JP (1) JP6567648B2 (pl)
ES (1) ES2951202T3 (pl)
PL (1) PL3179982T3 (pl)
WO (1) WO2016016908A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
HUE059639T2 (hu) 2015-01-26 2022-12-28 Bausch & Lomb Szemészeti szuszpenzió kompozíció
JP6856620B2 (ja) * 2015-07-27 2021-04-07 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 薬剤搭載ナノ樹脂粒子
US10020844B2 (en) 2016-12-06 2018-07-10 T&T Intellectual Property I, L.P. Method and apparatus for broadcast communication via guided waves
US11241443B2 (en) 2017-04-07 2022-02-08 Sun Pharma Advanced Research Company Ltd. Ophthalmic solution of bimatoprost
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019189720A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
WO2019189721A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
CN112788950A (zh) 2018-07-31 2021-05-11 微生物公司 用于治疗伤口的铋-硫醇组合物和方法
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2022115681A2 (en) * 2020-11-30 2022-06-02 Romeg Therapeutics Llc Methods and compositions for oral pilocarpine liquid
EP4277660A1 (en) * 2021-01-13 2023-11-22 Sun Pharma Advanced Research Company Ltd Method of reducing elevated intraocular pressure
US20240041869A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising an anti-allergen and a redness reduction agent
WO2024028816A1 (en) * 2022-08-04 2024-02-08 Bausch + Lomb Ireland Limited Ophthalmic composition comprising pilocarpine and a redness reduction agent

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3722837A1 (de) * 1987-07-10 1989-01-19 Ruetgerswerke Ag Ophthalmisches depotpraeparat
US5275820A (en) 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5296228A (en) 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
DE69837664T2 (de) 1997-05-14 2008-01-03 Senju Pharmaceutical Co., Ltd. Wässrige suspensionspräparationen mit exzellenter redispersibilität
CA2345466C (en) 1998-09-25 2007-01-23 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
WO2000069411A1 (en) 1999-05-12 2000-11-23 Alcon Laboratories, Inc. Use of polymeric adsorbents in pharmaceutical dosage forms
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
PL211494B1 (pl) * 2001-12-21 2012-05-31 Alcon Zastosowanie syntetycznych, nieorganicznych nanocząstek jako nośników dla leków i kompozycja farmaceutyczna do oczu lub uszu
BRPI0506983A (pt) * 2004-01-20 2007-07-03 Allergan Inc composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
US20050238695A1 (en) * 2004-04-27 2005-10-27 Atma Chaudhari Lozenge for delivery of dextromethorphan
US8821943B2 (en) * 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
NZ728721A (en) * 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
ES2951202T3 (es) * 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco

Also Published As

Publication number Publication date
US20210308130A1 (en) 2021-10-07
US11931359B2 (en) 2024-03-19
US10172852B2 (en) 2019-01-08
JP6567648B2 (ja) 2019-08-28
US20170239243A1 (en) 2017-08-24
US11058684B2 (en) 2021-07-13
ES2951202T3 (es) 2023-10-19
EP3954362A1 (en) 2022-02-16
US11951106B2 (en) 2024-04-09
EP3179982A4 (en) 2017-12-27
WO2016016908A1 (en) 2016-02-04
EP3179982B1 (en) 2023-07-19
US20190070176A1 (en) 2019-03-07
JP2017525686A (ja) 2017-09-07
US20230098352A1 (en) 2023-03-30
EP3179982A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
PL3179982T3 (pl) Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
IL280905A (en) Use of erythrohydroxybibopropion to increase drug level in plasma
IL279001A (en) Nasal medicines and methods of using them
IL252839A0 (en) Treatment of boils
ZA201608040B (en) Capacitor and method of production thereof
IL248730A0 (en) Drug delivery system and method of use
EP3142735A4 (en) Devices and methods for identification of medicament delivery devices
HK1245065A1 (zh) 可膨脹藥物遞送裝置和使用方法
HK1232109A1 (zh) 植入式醫療設備基於光的位置和識別
SG11201703184SA (en) A method of treatment
PL3183173T3 (pl) Opakowanie i sposób jego wytwarzania
GB201505819D0 (en) An orthotic and a method of making an orthotic
GB201419540D0 (en) Delivery of drugs
EP3474836C0 (en) OPHTHALMIC MEDICINE CONTAINING SALBUTAMOL.
EP3107537A4 (en) Compositions and methods for drug sensitization of parasites
GB2532942B (en) A container and method of manufacture
GB2545173B (en) An improved coffin and a method of constructing an improved coffin
GB201510576D0 (en) Implants and methods of forming thereof
GB201416797D0 (en) Contianer and method of use thereof
AU2014904178A0 (en) A method of treatment